S

Solventum

Global healthcare company: wound care, dental

Power Platform & AI Automation Engineer

Full-Time
No salary listed
Senior
Bachelor's
Bengaluru, Karnataka, India
HybridHybrid work location in Bangalore.
Software EngineeringAI Application Engineering

About the job

Requirements
  • A bachelor's degree or higher and six years of IT experience delivering automation or application solutions, or a high school diploma/GED and ten years of IT experience delivering automation or application solutions.
  • Three years of experience building solutions with Power Platform, including Power Apps canvas and model-driven applications, Power Automate flows with enterprise error-handling and resiliency patterns, Dataverse, and Copilot Studio.
  • Three years of PowerShell scripting experience for Microsoft 365 automation and administration, including Graph API.
  • Two years of hands-on Microsoft 365 administration experience with Entra ID, Exchange Online, Microsoft Teams, and SharePoint Online.
  • One year of experience building AI-enabled or agent-based solutions, such as Copilot Studio, Azure AI Foundry, or LLM-based automations.
  • Experience supporting production platforms and automation workloads, including incident response and root cause analysis.
Responsibilities
  • Lead end-to-end delivery of assigned automation backlog items using Power Apps, Power Automate, Copilot Studio, and PowerShell for Microsoft 365 automation, administration, and lifecycle management, following established architecture patterns, governance standards, and application lifecycle management guidance.
  • Implement Copilot Studio agents and AI-enabled automation for approved use cases, applying the organization’s governance, security, and lifecycle standards.
  • Determine root causes of automation failures, performance issues, and operational incidents; partner with the Architect on remediation planning and escalate systemic issues appropriately.
  • Support production automation and platform workloads in a backlog-driven, service-oriented model, contributing to documentation, operational runbooks, and knowledge-base articles.
  • Build and maintain Power BI reports and dashboards covering automation health, platform usage and adoption, and governance and audit metrics.
Desired Qualifications
  • Microsoft certifications such as PL-400 (Power Platform Developer), AB-620 (AI Agent Builder Associate), PL-200, MS-102 (Microsoft 365 Administrator), or AI-102 (Azure AI Engineer Associate).
  • Experience building and governing Copilot Studio agents or other AI/agent-based solutions, including knowledge sources, custom actions and connectors, prompt design, and responsible AI practices.
  • Experience delivering automation in regulated industries such as healthcare or life sciences, or in other compliance-driven environments.
  • Experience with Power Platform governance concepts, including DLP policies, environment strategy, app and flow lifecycle management, and Dataverse security roles.
  • Strong troubleshooting and debugging ability; comfort in backlog-driven delivery models; clear written communication; ability to consistently follow architectural direction; and effective use of AI-assisted development tools.

About the company

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Eagan, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9.5%, and management raised EPS guidance to $7.10-$7.20.
  • Solventum announced HIS separation on August 5, 2026, sharpening its MedTech focus.
  • The $200 million Eagan Innovation Hub supports roughly 20 launches over two years.

What critics are saying

  • Management expects HIS separation to cut margins about 400 basis points after offsets.
  • ERP cutover orders distorted Q2 2026; Q3 growth resets when demand normalizes.
  • Legal costs, restructuring, and separation complexity keep Solventum exposed until 2027-2028 transactions close.

What makes Solventum unique

  • Solventum combines MedSurg, Dental, and clinical workflow assets from 3M’s healthcare spinout.
  • Its 2026 Eagan Innovation Hub concentrates wound care, sterilization, and digital health R&D.
  • The company still sells into over 75% of U.S. hospitals through entrenched workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

0%

1 year growth

6%

2 year growth

9%
PR Newswire
Oct 19th, 2026
Solventum wins FDA clearance to combine Restrata Matrix with V.A.C. Therapy for wound healing

Solventum has received US Food and Drug Administration (FDA) 510(k) clearance to use Restrata Synthetic Electrospun Fiber Matrix together with its V.A.C. Therapy, the company announced on October 19, 2026. The clearance follows Solventum's acquisition of Acera Surgical in December 2025. Restrata is a fully synthetic, resorbable matrix that supports soft tissue repair, while V.A.C. Therapy applies negative pressure to promote wound healing. Solventum says the matrix resists enzymatic degradation and matches the dressing's wear time of up to seven days. Many collagen-based dressings degrade too early for such use. The pairing may mean fewer dressing changes and a more predictable workflow for care teams. "We're giving clinicians an effective way to streamline care and support better patient outcomes," said Kelley Moffett, president of Advanced Wound Care at Solventum.

Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.